Biblio

Export 111 results:
Author Title Type Year
Filters: Author is Zetterberg, Henrik  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Aged
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia., Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
J. Spiegel, Pirraglia, E., Osorio, R. S., Glodzik, L., Li, Y., Tsui, W., Louis, L. A. Saint, Randall, C., Butler, T., Xu, J., Zinkowski, R. P., Zetterberg, H., Fortea, J., Fossati, S., Wisniewski, T., Davies, P., Blennow, K., and de Leon, M. J., Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease., J Alzheimers Dis, vol. 49, no. 1, pp. 93-100, 2016.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years., J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease., J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
A. L. Jefferson, Gifford, K. A., Mae Y Acosta, L., Bell, S. P., Donahue, M. J., L Davis, T., Gottlieb, J. A., Gupta, D. K., Hohman, T. J., Lane, E. M., Libon, D. J., Mendes, L. A., Niswender, K., Pechman, K. R., Rane, S., Ruberg, F. L., Su, Y. Ru, Zetterberg, H., and Liu, D., The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview., J Alzheimers Dis, vol. 52, no. 2, pp. 539-59, 2016.
J. Cummings, Schwartz, G. G., Nicholls, S. J., Khan, A., Halliday, C., Toth, P. P., Sweeney, M., Johansson, J. O., Wong, N. C. W., Kulikowski, E., Kalantar-Zadeh, K., Lebioda, K., Ginsberg, H. N., Winblad, B., Zetterberg, H., and Ray, K. K., Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial., J Alzheimers Dis, vol. 83, no. 4, pp. 1703-1715, 2021.

Pages